ATAZANAVIR ALPHAPHARM atazanavir (as sulfate) 200 mg capsule bottle

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

atazanavir sulfate, Quantity: 227.8 mg (Equivalent: atazanavir, Qty 200 mg)

Available from:

Alphapharm Pty Ltd

Pharmaceutical form:

Capsule

Composition:

Excipient Ingredients: lactose monohydrate; crospovidone; magnesium stearate; titanium dioxide; brilliant blue FCF; purified water; erythrosine; Gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Administration route:

Oral

Units in package:

60

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Atazanavir is indicated for the treatment of HIV 1 infection, in combination with other antiretroviral agents. This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts from controlled studies (see CLINICAL TRIALS).

Product summary:

Visual Identification: No.0, blue opaque cap and greenish-blue opaque body, hard-shell gelatin capsule filled with white to pale yellow powder. The capsule is axially printed with MYLAN over AR200 in black ink on both the cap and body.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Authorization status:

Registered

Authorization date:

2018-08-28